Schering-Plough’s NDA for sugammadex has been assigned priority review status by the FDA. Sugammadex is specifically designed to reverse the effects of certain muscle relaxants, marketed in the U.S. as Zemuron and vecuronium bromide, which are used as part of general anesthesia. “Organon, now part of Schering-Plough Corporation, has had a strong presence in the anesthesia market for over 35 years,” said Robert J. Spiegel, M.D., chief medical officer and senior vice president...